220 related articles for article (PubMed ID: 27924636)
1. Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues.
Raccah D
Expert Opin Drug Saf; 2017 Feb; 16(2):227-236. PubMed ID: 27924636
[TBL] [Abstract][Full Text] [Related]
2. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents.
Cornell S
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):17-27. PubMed ID: 32910490
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
5. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
Hanefeld M; Raccah D; Monnier L
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):311-321. PubMed ID: 27776453
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.
Dahiya L; Kaur R; Kumar R; Kumar M; Palta K
Curr Diabetes Rev; 2020; 16(4):279-292. PubMed ID: 31057118
[TBL] [Abstract][Full Text] [Related]
7. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.
Peng H; Want LL; Aroda VR
Curr Diab Rep; 2016 May; 16(5):44. PubMed ID: 27037706
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus.
Forst T; Pfützner A
Expert Opin Pharmacother; 2013 Nov; 14(16):2281-96. PubMed ID: 24087882
[TBL] [Abstract][Full Text] [Related]
9. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.
Russell-Jones D
Int J Clin Pract; 2010 Sep; 64(10):1402-14. PubMed ID: 20716148
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.
Cimmaruta D; Maiorino MI; Scavone C; Sportiello L; Rossi F; Giugliano D; Esposito K; Capuano A
Expert Opin Drug Saf; 2016 Dec; 15(sup2):77-83. PubMed ID: 27875915
[TBL] [Abstract][Full Text] [Related]
11. [Safety and tolerability of GLP-1 receptor agonists].
Soldevila B; Puig-Domingo M
Med Clin (Barc); 2014; 143 Suppl 2():35-40. PubMed ID: 25326842
[TBL] [Abstract][Full Text] [Related]
12. Emerging GLP-1 receptor agonists.
Lund A; Knop FK; Vilsbøll T
Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus.
Karras SN; Rapti E; Koufakis T; Kyriazou A; Goulis DG; Kotsa K
Curr Clin Pharmacol; 2017; 12(4):202-209. PubMed ID: 29473524
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
Jespersen MJ; Knop FK; Christensen M
Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):17-29. PubMed ID: 23094590
[TBL] [Abstract][Full Text] [Related]
15. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
16. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
17. Novel GLP-1 receptor agonists for diabetes.
Garber AJ
Expert Opin Investig Drugs; 2012 Jan; 21(1):45-57. PubMed ID: 22111970
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
19. [The combination of GLP-1 analogs and SGLT2 inhibitors : new perspectives ?].
Ritz C; Jaafar J; Philippe J
Rev Med Suisse; 2017 May; 13(565):1134-1139. PubMed ID: 28639755
[TBL] [Abstract][Full Text] [Related]
20. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
